Optibiotix Health Plc (LON:OPTI) CEO Stephen O’Hara talks to DirectorsTalk about its European manufacturing, supply and profit sharing agreement with Sacco S.r.l. Stephen explains tells us more about the agreement and its pipeline for other agreements like this.
Optibiotix Health Plc is a life sciences company developing a range of products to modify the human microbiome. The Company’s principal activity is research and development into microbiome modulators. It operates in UK segment. The Company has a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is operated by its OptiScreen and OptiBiotic platform technologies designed to identify metabolic pathways and compounds that impact on human physiology. Its Optiscreen is a screening and optimization technology platform designed to identify microbes within the human microbiome with metabolic pathways, which can interact with human physiological processes. Its OptiBiotic is a platform technology, which generates compounds and screens them for their ability to modulate the human microbiome and its microbial end products. Its platforms are applicable across a range of other human diseases.